VeroScience collaborates on diabetes treatment

TIVERTON – VeroScience LLC, in collaboration with S2 Therapeutics of Bristol, Tenn., helped develop a drug to treat Type 2 diabetes, with a demonstrated cardiovascular safety profile.
Now, VeroScience, with 45 U.S. and international patents, wants to turn its research, focused on circadian neuroendocrine resetting therapy, to seek treatment for a wide variety of other diseases beyond diabetes, including cancer, anti-immune and reproductive disorders.
Its diabetes drug, Cycloset, was approved by the U.S. Food and Drug Administration in 2009. Type 2 diabetes can lead to multiple disorders, including heart disease, stroke, nerve damage, kidney problems and vision problems. It is a growing global pandemic, estimated to afflict about 350 million people by 2030.
Animals in the wild go through a marked annual cycle of metabolism, shifting between lean, insulin sensitive and obese, insulin resistant (diabetes-like) states at specific times of year, Cincotta said.
Within the next two to five years, Cincotta said he’d like to triple the number of VeroScience employees and consultants, which now number about 20, to develop therapies for other major diseases by utilizing the VeroScience technology. &#8226